Clavis Pharma A/S, which is developing lipid technology for delivering anti-cancer drugs, has appointed two new board members to replace three resigning members.
Following its annual general meeting on 20 May 2010, Anders Wiklund and Annette Clancy were named chairman and non-executive director respectively, replacing the former chairman, Keith McCullagh, and two other directors, Gert Caspritz and Stina Gestrelius.
Mr Wiklund has served in senior positions with several companies. His last job prior to joining Clavis was president of EffRx Inc, which is involved with delivery technology. He is also an advisor to venture capital funds.
Ms Clancy has had a long career with GlaxoSmithKline and is an advisor to Frazier Healthcare Ventures.
Copyright 2010 Evernow Publishing Ltd